Jame Abraham
Jame Abraham leads medical oncology at Cleveland Clinic and its breast cancer trial programme.
Breast medical oncologist and department chair; NCCN breast cancer panel member and investigator in adjuvant and metastatic breast cancer trials.
| Title | Journal | Year |
|---|---|---|
| Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) | Journal of Clinical Oncology | 2021 |
Pages like this
not linked directly; found by shared links- PersonShinji Ohno
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonClifford A. Hudis
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonJonas Bergh
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- ProductPegulicianine
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- InstitutionCleveland Clinic Abu Dhabi
Shares Cleveland Clinic Taussig Cancer Institute, HR-positive / HER2-negative breast cancer.
- IdeaPublic country dashboards for the three WHO breast cancer targets
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonThomas Bachelot
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- IdeaOne-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.